ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Kissei Pharmaceuticals Company Ltd (PK)

Kissei Pharmaceuticals Company Ltd (PK) (KSPHF)

25,77
0,00
(0,00%)
Fermé 13 Juin 10:00PM

Kissei Pharmaceuticals Company Ltd (PK) (KSPHF) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
25,77
( - )
Prix Achat
21,55
Prix Vente
27,44
Volume échangé
-
0,00 Fourchette du Jour 0,00
25,10 Plage de 52 semaines 31,90
Cap du marché
Clôture Veille
25,77
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
US$ 114 702
Actions en circulation
41 451 945
Rendement du Dividende (LTM)
120 (3,23%)
Ratio Cours sur Bénéfices
11,46
Bénéfice par action (BPA)
331,53
Chiffre d'affairess (LTM)
97,41B
Bénéfice net (LTM)
13,78B

À propos de Kissei Pharmaceuticals Company Ltd (PK)

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Miniri... Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. Kissei Pharmaceutical Co., Ltd. was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Matsumoto, Japan
Fondé
2026
Kissei Pharmaceuticals Company Ltd (PK) est coté dans le secteur Healthcare de la OTC Markets avec le ticker KSPHF. Le dernier cours de clôture d'Kissei Pharmaceuticals (PK) était de US$25,77. Au cours de la dernière année, les actions de Kissei Pharmaceuticals (PK) ont été négociées dans une fourchette de prix de US$ 25,10 à US$ 31,90.

Kissei Pharmaceuticals (PK) compte actuellement 41 451 945 actions en circulation. La capitalisation boursière d'Kissei Pharmaceuticals (PK) est de US$1,07 milliard. Kissei Pharmaceuticals (PK) a un ratio cours/bénéfice (ratio PE) de 11.46.

KSPHF Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120025.7725.7725.7700CS
26-1.2-4.4493882091226.9726.9725.771525.77CS
52-4.51-14.89431968330.2831.925.16627.77394477CS
1564.8823.3604595520.8931.919.32221423.24315158CS
2606.380732.908356670919.389331.917.0460719.97242313CS

KSPHF - Frequently Asked Questions (FAQ)

What is the current Kissei Pharmaceuticals Company Ltd (PK) share price?
The current share price of Kissei Pharmaceuticals Company Ltd (PK) is US$ 25,77
How many Kissei Pharmaceuticals Company Ltd (PK) shares are in issue?
Kissei Pharmaceuticals Company Ltd (PK) has 41 451 945 shares in issue
What is the market cap of Kissei Pharmaceuticals Company Ltd (PK)?
The market capitalisation of Kissei Pharmaceuticals Company Ltd (PK) is USD 1,07B
What is the 1 year trading range for Kissei Pharmaceuticals Company Ltd (PK) share price?
Kissei Pharmaceuticals Company Ltd (PK) has traded in the range of US$ 25,10 to US$ 31,90 during the past year
What is the PE ratio of Kissei Pharmaceuticals Company Ltd (PK)?
The price to earnings ratio of Kissei Pharmaceuticals Company Ltd (PK) is 11,46
What is the cash to sales ratio of Kissei Pharmaceuticals Company Ltd (PK)?
The cash to sales ratio of Kissei Pharmaceuticals Company Ltd (PK) is 1,62
What is the registered address of Kissei Pharmaceuticals Company Ltd (PK)?
The registered address for Kissei Pharmaceuticals Company Ltd (PK) is 19-48, Yoshino, Matsumoto, Nagano, 399-8710
What is the Kissei Pharmaceuticals Company Ltd (PK) website address?
The website address for Kissei Pharmaceuticals Company Ltd (PK) is www.kissei.co.jp
Which industry sector does Kissei Pharmaceuticals Company Ltd (PK) operate in?
Kissei Pharmaceuticals Company Ltd (PK) operates in the Pharmaceuticals sector

KSPHF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock